These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 38344968)

  • 1. [In searching for perfect blood substitute. Creation and application of perftorane].
    Krylov NN; Kazhlaev AY; Karpenko IV; Batoev SD
    Khirurgiia (Mosk); 2024; (2):111-117. PubMed ID: 38344968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perfluorocarbons in the twenty-first century: clinical applications as transfusion alternatives.
    Spence RK
    Artif Cells Blood Substit Immobil Biotechnol; 1995; 23(3):367-80. PubMed ID: 7493058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perfluorocarbon-based oxygen carriers: review of products and trials.
    Castro CI; Briceno JC
    Artif Organs; 2010 Aug; 34(8):622-34. PubMed ID: 20698841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blood substitutes and oxygen therapeutics: an overview and current status.
    Jahr JS; Nesargi SB; Lewis K; Johnson C
    Am J Ther; 2002; 9(5):437-43. PubMed ID: 12237737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perfluorocarbons: future clinical possibilities.
    Clark MC; Weiman DS; Pate JW; Gir S
    J Invest Surg; 1997; 10(6):357-65. PubMed ID: 9654392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perfluorocarbons and haemoglobin solutions: will they ever reach clinical practice?
    Lamy M; Deby-Dupont G
    Acta Anaesthesiol Belg; 2003; 54(4):299-300. PubMed ID: 14719348
    [No Abstract]   [Full Text] [Related]  

  • 7. Perfluorocarbons as blood substitutes: the early years. Experience with Fluosol DA-20% in the 1980s.
    Spence RK; Norcross ED; Costabile J; McCoy S; Cernaianu AC; Alexander JB; Pello MJ; Atabek U; Camishion RC
    Artif Cells Blood Substit Immobil Biotechnol; 1994; 22(4):955-63. PubMed ID: 7849967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Results of perftorane local use in complex treatment of patients with odontogenic phlegmons of the face and neck].
    Agapov VS; Piminova IA
    Stomatologiia (Mosk); 2006; 85(5):32-5. PubMed ID: 17159841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The corrective effect of perfluorocarbon emulsions on the cerebral hemodynamics in craniocerebral trauma].
    Krivoshapkin AL; Krivoshapkin AL; Semenycheva TV
    Zh Vopr Neirokhir Im N N Burdenko; 1992; (6):17-9. PubMed ID: 1337408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The use of perfluorocarbon emulsions for suppression of rejection reaction in kidney allotransplantation].
    Ilgiavishute IaS; Zhukauskas GIu; Dapshis KL; Onishchenko NA
    Khirurgiia (Mosk); 1993 May; (5):16-8. PubMed ID: 8089979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perfluorocarbon-based oxygen delivery.
    Riess JG
    Artif Cells Blood Substit Immobil Biotechnol; 2006; 34(6):567-80. PubMed ID: 17090429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical potential of intravenously administered perfluorocarbons.
    Habler O; Kleen M; Messmer K
    Acta Anaesthesiol Scand Suppl; 1997; 111():256-8. PubMed ID: 9421036
    [No Abstract]   [Full Text] [Related]  

  • 13. The initial response of blood leukocytes to incubation with perfluorocarbon blood substitute emulsions.
    McDonagh PF; Wilson DS
    Artif Cells Blood Substit Immobil Biotechnol; 1995; 23(3):439-47. PubMed ID: 7493065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perfluorocarbon-based oxygen carriers: from physics to physiology.
    Jägers J; Wrobeln A; Ferenz KB
    Pflugers Arch; 2021 Feb; 473(2):139-150. PubMed ID: 33141239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Biophysics at the turn of the new millenium: perfluorocarbon media and gas-transporting blood substitutes].
    Ivanitskiĭ GR
    Biofizika; 2001; 46(1):5-33. PubMed ID: 11236562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of current generation perfluorocarbon emulsions in cardiac surgery.
    Holman WL; McGiffin DC; Vicente WV; Spruell RD; Pacifico AD
    Artif Cells Blood Substit Immobil Biotechnol; 1994; 22(4):979-90. PubMed ID: 7849969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical results of perftorane use in comprehensive treatment of patients with odontogenic phlegmons].
    Durnovo EA; Furman IV
    Stomatologiia (Mosk); 2007; 86(4):35-9. PubMed ID: 17828096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of the perfluorocarbon Fluosol-DA in coronary angioplasty.
    Kerins DM
    Am J Med Sci; 1994 Mar; 307(3):218-21. PubMed ID: 8160713
    [No Abstract]   [Full Text] [Related]  

  • 19. Rationale for the clinical studies of anemia treated with the perfluorochemical emulsion: Fluosol DA 20%.
    Tremper KK
    Prog Clin Biol Res; 1983; 122():307-13. PubMed ID: 6348785
    [No Abstract]   [Full Text] [Related]  

  • 20. Increased antioxidant capacity, suppression of free radical damage and erythrocyte aggrerability after combined application of alpha-tocopherol and FC-43 perfluorocarbon emulsion in early postburn period in rats.
    Bekyarova G; Yankova T; Galunska B
    Artif Cells Blood Substit Immobil Biotechnol; 1996 Nov; 24(6):629-41. PubMed ID: 8922232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.